Wednesday, February 10, 2010, 7:09pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Sangamo Biosciences Inc. (SGMO)

At 5:00AM SGT: 4.85 USD   0.00 (0.00%)  
 MORE ON SGMO 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Sangamo BioSciences, Inc. (NGM:SGMO) Delayed quote dataEdit
Last Trade:4.85 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:4.85
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:8.60
Day's Range:N/A - N/A
52wk Range:2.68 - 9.39
Volume:0
Avg Vol (3m):259,616
Market Cap:217.80M
P/E (ttm):N/A
EPS (ttm):-0.46
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add SGMO to Portfolio   Download Data

 HEADLINES 
•New Star Analyst Rankings for Sangamo BioSciences, Inc.
StarMine (Thu, Feb 4)
•Sangamo BioSciences, Inc. Q4 2009 Earnings Call Transcript
at Seeking Alpha (Thu, Feb 4)
•SANGAMO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
EDGAR Online (Thu, Feb 4)
•Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
PR Newswire (Thu, Feb 4)
•Q4 2009 Sangamo BioSciences Earnings Release - After Market Close
CCBN (Wed, Feb 3)
•Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
PR Newswire (Tue, Feb 2)
•Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
PR Newswire (Thu, Jan 28)
•Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 1 Safety Trial of SB-728-T for HIV/AIDS
PR Newswire (Tue, Jan 19)
•Stocks to Watch at Biotech’s Bellwether Conference
at Minyanville.com (Tue, Jan 12)
•Sangamo plans another mid-stage neuropathy trial
at Reuters (Mon, Jan 11)
More Headlines for SGMO...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.46
EPS Est (in 2 years) (Dec-10) :-0.30
Avg Rec (current)*:2.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices